Latest Biodistribution Stories
ANN ARBOR, Mich., Oct. 4, 2012 /PRNewswire/ -- Molecular Imaging, Inc. has expanded its preclinical nuclear medicine program with the addition of Single Photon Emission Computed Tomography (SPECT) imaging. This decision was driven by the growing industry understanding of the value of in vivo molecular imaging throughout the entire drug development process. SPECT is an exciting preclinical modality that allows researchers to 'tag' potential treatments with a variety of radioactive...
Nanoparticle could allow diagnosis, treatment in one visitResearchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat. The all-in-one particle is one of the first examples from a growing field called "theranostics" that develops technologies physicians can use to diagnose and treat diseases in a single...
Fully integrated PET/MRI system could advance research, say researchers at SNM's 56th Annual MeetingAÂ new PET/MR imaging system has been developed that can successfully provide whole-body images of rats and other small animals, according to researchers at SNM's 56th Annual Meeting in Toronto. The new system could greatly improve imaging capabilities and advance research in many areas."Our system shows great promise because it is able to simultaneously provide the complementary...
BioReliance Corporation announced today that Dr. Sarah Sheridan, a Scientific Director in BioReliance's Glasgow, Scotland, facility, will deliver a poster presentation regarding her work in gene therapy biodistribution studies at the 16th Annual European Society of Gene and Cell Therapy conference to be held from November 13-16, 2008 in Bruges, Belgium. BioReliance is a leading contract services company that provides biologics safety testing, toxicology, viral manufacturing and laboratory...
By Anonymous Hooker et al. from the University of California-Berkeley reported on April 25 ahead of print in Molecular Imaging and Biology on a modular synthetic strategy to append imaging agents to a viral capsid. The researchers labeled the inside surface of the hollow protein shell of bacteriophage MS2 (mtMS2) with ^sup 18^F- fluorobenzaldehyde through a multistep bioconjugation strategy. An aldehyde functional group was first attached to interior tyrosine residues through a diazonium...
QuantRx Biomedical has announced that the company's FluoroPharma has achieved positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging. The Phase I trial was designed to evaluate safety, distribution and dosimetry of BFPET in 12 healthy subjects following a single dose injection at rest. BFPET is FluoroPharma's second cardiovascular product to complete Phase I clinical development. BFPET is a positron emission tomography (PET) imaging agent,...
BOSTON, July 23 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging. BFPET is FluoroPharma's second cardiovascular product to complete Phase I clinical development. BFPET is a PET imaging agent, designed to assess the blood flow in the heart (myocardial perfusion). Myocardial perfusion...
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today presents Phase I data relating to the safety and tolerability in human subjects of BMS747158, its novel fluorine 18-labeled Positron Emission Tomography (PET) tracer for myocardial perfusion imaging. The presentation was made by the Principal Investigator, Dr. Jamshid Maddahi, at the 55th Annual Meeting of the SNM in New Orleans, Louisiana. The preliminary clinical findings indicate that when used with PET...
